Advertisement

Tumor Biology

, Volume 37, Issue 7, pp 9549–9554 | Cite as

Association of MDR1 single-nucleotide polymorphisms and haplotype variants with multiple myeloma in Chinese Jiangsu Han population

  • Guangli Yin
  • Zhengrui Xiao
  • Ying Ni
  • Xiaoyan Qu
  • Hanxin Wu
  • Hua Lu
  • Sixuan Qian
  • Lijuan Chen
  • Jianyong Li
  • Hairong Qiu
  • Kourong Miao
Original Article

Abstract

Multidrug resistance 1 (MDR1) gene encodes P-glycoprotein (P-gp), which acts as an efflux pump and provides cell protection against various substances, and its single-nucleotide polymorphisms (SNPs) are associated with the development of malignant hematologic diseases. The present study aimed at investigating whether the MDR1 SNPs and haplotype variants were correlated with the susceptibility to multiple myeloma (MM). A total of 115 MM patients and 153 healthy controls from Jiangsu Han population were enrolled and genotyped by polymerase chain reaction–allele-specific primer (PCR-ASP) method or DNA direct sequencing at MDR1 loci of C1236T, G2677T/A, and C3435T. No significance was found in the distribution of alleles and genotypes in MDR1 three loci. Diplotype analysis has also demonstrated no effect in susceptibility to MM. But, in haplotype analysis, the haplotype of T–G–T was significantly more common than healthy controls (12.6 % in MM group vs. 1.7 % in control group, odds ratios (ORs) = 8.7, 95 % confidence interval (CI) 3.3–22.8, Pc< 0.01). Our results pointed out that comparable allele, genotype, and diplotype frequencies among MM patients and controls in Chinese Jiangsu Han population were found; the frequency of T–G–T haplotype was significantly increased in MM group compared with the control group, which indicated that this haplotype might be associated with the susceptibility to MM.

Keywords

Multiple myeloma (MM) Multidrug resistance 1 (MDR1Single-nucleotide polymorphism (SNP) 

Notes

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (81470329, 81302040, 81372540), National Public Health Grand Research Foundation (No. 201202017), Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institute (No. JX10231801), Project of National Key Clinical Specialty, National Science & Technology Pillar Program (No. 2014BAI09B12), and Project Funded by Jiangsu Provincial Special Program of Medical Science (No. BL2014086).

Compliance with ethical standards

Conflicts of interest

None.

References

  1. 1.
    Sauna ZE, Kim IW, Ambudkar SV. Genomics and the mechanism of P-glycoprotein (ABCB1). J Bioenerg Biomembr. 2007;39:481–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Bodor M, Kelly EJ, Ho RJ. Characterization of the human MDR1gene. AAPS J. 2005;7(1):E1–5.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Vine J, Cohen SB, Ruchlemer R, Goldschmidt N, Levin M, Libster D, et al. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. Leuk Lymphoma. 2014;55:2525–31.CrossRefPubMedGoogle Scholar
  4. 4.
    Yue Q, Xiong B, Chen L, Chen Y, Bu F, Liu X, et al. MDR1 C3435T polymorphism and childhood acute lymphoblastic leukemia susceptibility: an updated meta-analysis. Biomed Pharmacother. 2015;69:76–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Ma L, Liu H, Ruan L, Yang X, Yang H, Feng Y. Multidrug resistance gene 1 C1236T polymorphism and susceptibility to leukemia: a meta-analysis. Biomed Rep. 2015;3:83–7.PubMedGoogle Scholar
  6. 6.
    Kim HN, Kim NY, Yu L, Kim YK, Lee IK, Yang DH, et al. Polymorphisms in DNA repair genes and MDR1 and the risk for non-Hodgkin lymphoma. Int J Mol Sci. 2014;15:6703–16.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ni Y, Xiao Z, Yin G, Fan L, Wang L, Zhu H, et al. The single nucleotide polymorphism and haplotype analysis of MDR1 in Chinese diffuse large B cell lymphoma patients. Biomed Pharmacother. 2015;73:24–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Dong HJ, Miao KR, Qiao C, Zhuang Y, Shen WY, Hong M, et al. Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population. Leuk Lymphoma. 2011;52:1003–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Amend SR, Wilson WC, Chu L, Lu L, Liu P, Serie D, et al. Whole genome sequence of multiple myeloma-prone C57BL/KaLwRij mouse strain suggests the origin of disease involves multiple cell types. PLoS One. 2015;10(5):e0127828.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: WHO; 2008.Google Scholar
  11. 11.
    Qiu H, Dong H, Pan S, Miao K. The single nucleotide polymorphism and haplotype analysis of MDR1 in Jiangsu Han population of China. Biomed Pharmacother. 2012;66:459–63.CrossRefPubMedGoogle Scholar
  12. 12.
    Excoffier L, Laval G, Schneider S. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinformatics Online. 2005;1:47–50.Google Scholar
  13. 13.
    Oj D. Multiple comparisons among means. J Am Stat Assoc. 1961;56:52–6.CrossRefGoogle Scholar
  14. 14.
    Gutierrez-Rubio SA, Quintero-Ramos A, Duran-Cardenas A, Franco-Topete RA, Castro-Cervantes JM, Oceguera-Villanueva A, et al. 1236 C/T and 3435 C/T polymorphisms of the ABCB1 gene in Mexican breast cancer patients. Genet Mol Res. 2015;14:1250–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Pongstaporn W, Pakakasama S, Chaksangchaichote P, Pongtheerat T, Hongeng S, Permitr S. MDR1 C3435T and C1236T polymorphisms: association with high-risk childhood acute lymphoblastic leukemia. Asian Pac J Cancer Prev. 2015;16:2839–43.CrossRefPubMedGoogle Scholar
  16. 16.
    Yaya K, Hind D, Meryem Q, Asma Q, Said B, Sellama N. Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia. Tumour Biol. 2014;35:10969–75.CrossRefPubMedGoogle Scholar
  17. 17.
    Mhaidat NM, Alshogran OY, Khabour OF, Alzoubi KH. MatalkaII, Haddadin WJ, et al. Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin’s lymphoma. J Exp Clin Cancer Res. 2011;30:68.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Drain S, Catherwood MA, Orr N, Galligan L, Rea IM, Hodkinson C, et al. ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leuk Lymphoma. 2009;50:566–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Ni Y, Yin G, Xiao Z, Fan L, Wang L, Wu Y, et al. MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients. Tumour Biol. 2015 Aug 19.Google Scholar
  20. 20.
    Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, Qiu HR, et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol. 2011;28(1):265–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2010;89(11):1133–40.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Maggini V, Buda G, Martino A, Presciuttini S, Galimberti S, Orciuolo E, et al. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics. 2008;18(5):383–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Jamroziak K, Balcerczak E, Calka K, Piaskowski S, Urbanska-Rys H, Salagacka A, et al. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res. 2009;33(2):332–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Lardo M, Castro M, Moiraghi B, Rojas F, Borda N, Rey JA, et al. MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia. Blood Res. 2015;50(3):154–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Sheng X, Zhang L, Tong N, Luo D, Wang M, Xu M, et al. MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case–control studies. Mol Biol Rep. 2012;39:7237–49.CrossRefPubMedGoogle Scholar
  26. 26.
    Bellusci CP, Rocco C, Aulicino P, Mecikovsky D, Curras V, Hegoburu S, et al. Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children. Gene. 2013;522(1):96–101.CrossRefPubMedGoogle Scholar
  27. 27.
    Wang D, Sadee W. Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J. 2006;8:E515–20.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002;71:297–303.CrossRefPubMedGoogle Scholar
  29. 29.
    Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 2002;12:437–50.CrossRefPubMedGoogle Scholar
  30. 30.
    Shen LX, Basilion JP, Stanton Jr VP. Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci U S A. 1999;96:7871–6.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Perloff MD, von Moltke LL, Störmer E, Shader RI, Greenblatt DJ. Saint John’s wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol. 2001;134:1601–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Guangli Yin
    • 1
    • 2
  • Zhengrui Xiao
    • 1
    • 2
  • Ying Ni
    • 1
    • 2
  • Xiaoyan Qu
    • 1
    • 2
  • Hanxin Wu
    • 1
    • 2
  • Hua Lu
    • 1
    • 2
  • Sixuan Qian
    • 1
    • 2
  • Lijuan Chen
    • 1
    • 2
  • Jianyong Li
    • 1
    • 2
  • Hairong Qiu
    • 1
    • 2
  • Kourong Miao
    • 1
    • 2
  1. 1.Department of HematologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjingChina
  2. 2.Collaborative Innovation Center for Cancer Personalized MedicineNanjing Medical UniversityNanjingChina

Personalised recommendations